ARMP Armata Pharmaceuticals
- 2.760
- +0.229+9.06%
Armata Pharmaceuticals News
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Armata Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 101.15% HC Wainwright & Co. $7 → $7 Maintains Buy 08/14/2023 101.15% HC Wainwright & Co. $7 → $
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
04:09 PM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
Armata Pharmaceuticals Q4 EPS $(0.55) Misses $(0.35) Estimate, Sales $1.53M Beat $860.00K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 89.66 percent decrease over losses
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Armata Pharmaceuticals 4Q Loss/Shr 55c >ARMP
Press Release: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES, March 21, 2024 LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata P
Press Release: Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement With Innoviva
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire LOS ANGELES, March 4, 2024 Proceeds to be used to continue to advance rigorously designed clinical tr
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSana Biotechnology (NASDAQ:SANA) shares increased by 45.2% to $7.49 during Wednesday's regular session. The company's market cap stands at $1.4 billion. Amarin Corp (NASDAQ:AMRN) stock increase
Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates
Armata Pharmaceuticals: A Promising Buy Based on Therapeutic Pipeline, Financial Stability, and Strategic Partnerships
Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals' Buy Rating
Armata Pharmaceuticals Q3 EPS $(0.86) Misses $(0.31) Estimate, Sales $1.23M Beat $950.00K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.31) by 177.42 percent. This is a 258.33 percent decrease over losse
Armata Pharmaceuticals 3Q Loss/Shr 86c >ARMP
Armata Pharmaceuticals 3Q Loss/Shr 86c >ARMP
Armata Pharmaceuticals Announces Presentation of Topline Data From SWARM-P.a. Clinical Study Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients At North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces Presentation of Topline Data From SWARM-P.a. Clinical Study Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients At North Ame
Analysis
Price Target
No Data
